Purpose: To explore feasibility, tolerability, dosimetry and probable efficacy of intravenous endoradiotherapy with carrier-added 4-[(131)I]iodo-L-phenylalanine (c.a. (131)I-IPA) in refractory high-grade glioma.
Methods: Two male patients (45 and 50 years), with long-standing, extensively pre-treated gliomas and evidence of progression underwent single intravenous injections of 2 and 4 GBq of c.a. (131)I-IPA, respectively. Tumour targeting was verified by (131)I-IPA single-photon emission computed tomography (SPECT). Metabolic and morphological changes indicative of tumour response were assessed by sequential [(18)F]fluoroethyltyrosine ((18)F-FET) positron emission tomography (PET) and contrast-enhanced magnetic resonance imaging (MRI) following therapy. Further monitoring included clinical state, safety laboratory, quality of life and dosimetry. Absorbed mean organ and whole-body doses were determined according to the Medical Internal Radiation Dose (MIRD) scheme using OLINDAEXM based on serial planar scintigraphy.
Results: Both patients tolerated the treatment well. No evidence of acute or delayed organ toxicity was observed. (131)I-IPA accumulated in the tumour recurrences identified by MRI/(18)F-FET. In patient 1, PET showed progressively decreasing maximum standardised uptake values (SUVmax) over 10 months, indicating metabolic response, paralleled by reduced contrast enhancement and tumour volume on MRI. Progression occurred 18 months after therapy. Treatment was repeated using 6.6 GBq of (131)I-IPA, to which no response was observed. Patient 2, followed-up for 3 months after therapy, showed stable disease on MRI and PET. Mean absorbed whole body doses ranged from 0.13 to 0.17 mSv/MBq, with the highest absorbed organ doses to kidneys, bladder and heart (0.86-1.23; 0.49-0.6 and 0.45-0.56 mSv/MBq).
Conclusion: Systemic endoradiotherapy using up to 6.6 GBq of c.a.(131)I-IPA is not associated with clinically detectable toxicity. Measurable anti-tumour effects in gliomas were observed. (131)I-IPA warrants further evaluation as glioma therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043044 | PMC |
| http://dx.doi.org/10.1007/s13139-011-0116-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alpha-Emitting Radionuclides: Current Status and Future Perspectives.
Pharmaceuticals (Basel)
January 2024
Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
The use of radionuclides for targeted endoradiotherapy is a rapidly growing field in oncology. In particular, the focus on the biological effects of different radiation qualities is an important factor in understanding and implementing new therapies. Together with the combined approach of imaging and therapy, therapeutic nuclear medicine has recently made great progress.
View Article and Find Full Text PDFRefined Chelator Spacer Moieties Ameliorate the Pharmacokinetics of PSMA-617.
Front Chem
August 2022
Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Article Synopsis
- Researchers developed new PSMA binding tracers for targeting prostate tumors, improving upon the existing radiopharmaceutical PSMA-617 by creating novel PSMA ligands with a benzyl group using solid-phase synthesis.* -
- These new tracers were successfully labeled with Gallium (Ga) or Lutetium (Lu) and showed promising results in stability, binding potency, and tumor targeting in experiments using a human prostate cancer cell line and mouse models.* -
- PET imaging demonstrated that the new ligands, particularly Ga-CA028 and Ga-CA030, provided high-contrast detection of tumors and lower kidney uptake compared to the standard PSMA-617, indicating their potential for clinical use in targeting metastatic prostate cancer.*
Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment.
Pharmaceutics
November 2020
Department of Biomedical Engineering, University of Alabama at Birmingham (UAB), 1825 University Blvd, Birmingham, AL 35294, USA.
Neuroendocrine (NE) cancers arise from cells within the neuroendocrine system. Chemotherapies and endoradiotherapy have been developed, but their clinical efficacy is limited. The objective of this study was to develop a dual-targeted extracellular vesicles (EV)-delivered combined therapies to treat NE cancer.
View Article and Find Full Text PDFThe College of Nuclear Physicians of South Africa Practice Guidelines on Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumours.
S Afr J Surg
September 2018
Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa.
Background: Peptide receptor radionuclide therapy (PRRT) for metastatic or inoperable neuroendocrine tumours (NETs) is a systemic therapy which targets somatostatin receptors overexpressed by differentiated NETs for endoradiotherapy. This guideline has been compiled by the College of Nuclear Physicians of the Colleges of Medicine of South Africa, with endorsement by the South African Society of Nuclear Medicine and the Association of Nuclear Physicians to guide Nuclear Medicine Physicians in its application during the management of these patients.
Recommendations: Patients with well- to moderately-differentiated NETs should be comprehensively worked-up to determine their suitability for PRRT.
Targeting prostate cancer: Prostate-specific membrane antigen based diagnosis and therapy.
Med Res Rev
January 2019
Department for Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
The high incidence rates of prostate cancer (PCa) raise demand for improved therapeutic strategies. Prostate tumors specifically express the prostate-specific membrane antigen (PSMA), a membrane-bound protease. As PSMA is highly overexpressed on malignant prostate tumor cells and as its expression rate correlates with the aggressiveness of the disease, this tumor-associated biomarker provides the possibility to develop new strategies for diagnostics and therapy of PCa.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!